Seminars in Oncology
Volume 30, Issue 1 , Pages 9-25 , February 2003

Chemotherapy for small cell lung cancer

References 

  1. Jemal A, Thomas A, Murray T, et al.  Cancer statistics 2002. CA Cancer J Clin. 2002;52:23–47
  2. Kristjansen PEG, Hansen HH. Management of small cell lung cancer: A summary of the Third International Association for the Study of Lung Cancer Workshop on Small Cell Lung Cancer. J Natl Cancer Inst. 1990;82:263–266
  3. Ihde DC. Chemotherapy of lung cancer. N Engl J Med. 1992;327:1434–1441
  4. Blackstein ME. Advances in chemotherapy for small cell lung cancer. Semin Oncol. 1994;21(suppl 11):38–42
  5. Maurer LH, Tulloh M, Weiss R, et al.  A randomized combined modality trial in small cell carcinoma of the lung. Cancer. 1980;45:30–39
  6. Woods RL, Levi JA, et al.  Chemotherapy for small cell lung cancer (SCLC): A randomised study of maintenance therapy with cyclophosphamide, adriamycin and vincristine (CAV) after remission induction with cis-platinum (CIS DDP), VP16-213 and radiotherapy. Proc Am Soc Clin Oncol. 1984;3:214; (abstr)
  7. Cullen M, Morgan D, Gregory W, et al.  Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: A randomised, controlled trial. Cancer Chemother Pharmacol. 1986;17:157–160
  8. Byrne MJ, Van Hazel G, Trotter J, et al.  Maintenance chemotherapy in limited small cell lung cancer: A randomised controlled clinical trial. Br J Cancer. 1989;60:413–418
  9. Bleehen NM, Fayers PM, Girling DJ, et al.  Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Br J Cancer. 1989;59:584–590
  10. Ettinger DS, Finkelstein DM, Abeloff MD, et al.  A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: A phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol. 1990;8:230–240
  11. Lebeau B, Chastang CL, Allard P, et al.  Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: Definitive results of a randomized clinical trial. Eur Respir J. 1992;5:286–290
  12. Giaccone G, Dalesio O, McVie GJ, et al.  Maintenance chemotherapy in small-cell lung cancer: Long-term results of a randomized trial. J Clin Oncol. 1993;11:1230–1240
  13. Jarry O, Fournel P, et al.  A randomised trial of 4 versus 8 courses of chemotherapy with ifosfamide epirubicin and etoposide (EVI) in extensive small cell lung cancer (SCLC). Denver, CO: International Association for the Study of Lung Cancer–Small Cell Lung Cancer,; 1994; (abstr)
  14. Beith JM, Clarke SJ, Woods RL, et al.  Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung. Eur J Cancer. 1996;32A:438–443
  15. Sculier JP, Paesmans M, Bureau G, et al.  Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. J Clin Oncol. 1996;14:2337–2344
  16. Spiro SG, Souhami RL, Geddes DM, et al.  Duration of chemotherapy in small cell lung cancer: A Cancer Research Campaign trial. Br J Cancer. 1989;59:578–583
  17. Johnson DH, Kim K, Sause W, et al.  Cisplatin (p) & etoposide (e) + thoracic radiotherapy (TRT) administered once or twice daily (bid) in limited stage (LS) small cell lung cancer (sclc): Final report of intergroup trial 0096. Proc Am Soc Clin Oncol. 1996;15:374; (abstr)
  18. Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: Implications for systemic therapy. Cancer Res. 1984;44:3643–3653
  19. Loehrer PJ, Einhorn LH, Greco FA. Cisplatin plus etoposide in small cell lung cancer. Semin Oncol. 1988;15:2–8
  20. Einhorn LH, Crawford J, Birch R, et al.  Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. J Clin Oncol. 1988;6:451–456
  21. Evans WK, Feld R, Murray N, et al.  Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. Ann Intern Med. 1987;107:451–458
  22. Fukuoka M, Furuse K, Saijo N, et al.  Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst. 1991;83:855–861
  23. Roth BJ, Johnson DH, Einhorn LH, et al.  Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992;10:282–291
  24. Murray N, Shah A, Osoba D, et al.  Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol. 1991;9:1632–1638
  25. Furuse K, Fukuoka M, Nishiwaki Y, et al.  Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. J Clin Oncol. 1998;16:2126–2132
  26. Murray N, Livingston RB, Shephers FA, et al.  Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: An Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol. 1999;17:2300–2308
  27. Cohen MH, Creaven PJ, Fossieck BE, et al.  Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep. 1977;61:349–354
  28. Dinwoodie WR, Lyman GH, Williams CC, et al.  Intensive combination chemotherapy and radiotherapy for small cell bronchogenic carcinoma (SCBC). Proc Am Assoc Cancer Res. 1981;22:505; (abstr)
  29. Mehta C, Vogl SE, Farber S, et al.  High-dose cyclophosphamide (c) in the induction (ind) chemotherapy (ct) of small cell lung cancer (sclc)—Minor improvements in rate of remission and survival. Proc Am Assoc Cancer Res. 1982;23:165; (abstr)
  30. Figueredo AT, Hryniuk WM, Strautmanis I, et al.  Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol. 1985;3:54–64
  31. Johnson DH, Einhorn LH, Birch R, et al.  A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1987;5:1731–1738
  32. Arriagada R, Le Chevalier T, Pierre Pignon J, et al.  Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med. 1993;25:1848–1852
  33. Ihde DC, Mulshine JL, Kramer BS, et al.  Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 1994;12:2022–2034
  34. Steward WP, von Pawel J, Gatzemeier U, et al.  Effects of granulocyte colony-stimulating factor and dose-intensification of V-ICE chemotherapy in small-cell lung cancer: A prospective randomized study of 300 patients. J Clin Oncol. 1998;16:642–650
  35. Thatcher N, Girling DJ, Hopwood P, et al.  Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: Results of a British Medical Research Council multicenter randomized trial. J Clin Oncol. 2000;18:395–404
  36. a. Bunn PA, Crowley J, Kelly K, et al.  Chemoradiotherapy with/without granulocyte-macrophage colony-stimulating factor in the treatment of limited stage small cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol. 1995;13:1632–1641
  37. Sculier JP, Paesmans M, Lecomte J, et al.  A three arm phase III randomized trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. Br J Cancer. 2001;85:1444–1451
  38. Antman KH, Souhami RL, et al.  High-dose chemotherapy in solid tumors. A review of published data in selected tumors and commentary. Ann Oncol. 1993;4(suppl 1):29–44
  39. Humblet Y, Symann M, Bosly A, et al.  Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: A randomized study. J Clin Oncol. 1987;5:1864–1873
  40. Elias A, Ayash L, Frei E, et al.  Intensive combined modality therapy for limited-stage small-cell lung cancer. J Natl Cancer Inst. 1993;85:559–566
  41. Slevin ML, Clark PI, Joel SP, et al.  A randomized trial to evaluate the effect of scheduling of on the activity of etoposide in small cell lung cancer. J Clin Oncol. 1989;7:1333–1340
  42. Clark PI, Cottier B. The activity of 10-, 14-, and 21-day schedules of single agent etoposide in previously untreated patients with extensive small cell lung cancer. Semin Oncol. 1992;19(suppl 14):36–39
  43. Smit EF, Postmus PE. A phase II study of oral etoposide 100 mg/day for 21 days every 4 weeks in untreated elderly and poor performance status small cell lung cancer patients. Cancer Treat Res. 1991;7:136; (abstr)
  44. Doward AJ. A prospective study of low dose oral etoposide in poor prognosis small cell lung cancer. Cancer Treat Res. 1991;7:111; (abstr)
  45. Medical Research Council Lung Cancer Working Party . Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomised trial. Lancet. 1996;348:563–566
  46. Harper P, Underhill C, Ruiz de Elvira MC, et al.  A randomized study of oral etoposide versus combination chemotherapy in poor prognosis small cell lung cancer. Proc Am Soc Clin Oncol. 1996;15:27; (abstr)
  47. Negoro S, Fukuoka M, Niitani H, et al.  Phase II study of cpt-11, new camptothecin derivative, in small cell lung cancer (sclc). Proc Am Soc Clin Oncol. 1991;10:241; (abstr)
  48. Masuda N, Fukuoka M, Kusunoki Y, et al.  CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992;10:1225–1229
  49. Smyth JF, Smith IE, Sessa C, et al.  Activity of docetaxel (Taxotere) in small cell lung cancer. Eur J Cancer. 1994;30A:1058–1060
  50. Cormier Y, Eisenhauer E, Muldal A, et al.  Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (sclc). National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 1994;75:283–285
  51. Ettinger D, Findelstein D, Ritch P, et al.  Randomized trial of single agents vs combination chemotherapy in extensive stage small cell lung cancer (sclc). Proc Am Soc Clin Oncol. 1992;11:295; (abstr)
  52. Ettinger D, Finkelstein DM, Sarma RP, et al.  Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol. 1995;13:1430–1435
  53. Kirschling RJ, Jung SH, Jett JR, et al.  A phase II trial of Taxol and GCSF in previously untreated patients with extensive stage small cell lung cancer (scc). Proc Am Soc Clin Oncol. 1994;13:326; (abstr)
  54. Wanders J, Ardizzoni A, Hansen HH, et al.  Phase II study of topotecan in refractory and sensitive small cell lung cancer (sclc). Proc Am Assoc Cancer Res. 1995;36:237; (abstr)
  55. Schiller JH, Kim K, Hutson P, et al.  Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial. J Clin Oncol. 1996;14:2345–2352
  56. Jassem J, Karnicka-Mlodkowska H, Van Pottelsberghe CH, et al.  Phase II study of vinorelbine (navelbine) in previously treated small cell lung cancer patients. Eur J Cancer. 1993;29A:1720–1722
  57. Furuse K, Kubota K, Kawahara M, et al.  Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Oncology. 1996;53:169–172
  58. Evans WK, Stewart DJ, Shepherd FA, et al.  VP-16, ifosfamide, and cisplatin (VIP) for extensive small cell lung cancer. Eur J Cancer. 1994;30A:299–303
  59. Loehrer PJ, Rynard S, Ansari R, et al.  Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer. Cancer. 1992;69:669–673
  60. Munoz MA, Arrivi A, Guaraz R, et al.  VP-16, ifosfamide, and cisplatin (VIP) as treatment of small cell lung cancer: A preliminary report. In: Presented at Fourth European Conference on Clinical Oncology and Cancer Nursing, Madrid, Spain, Federation of European Cancer Societies. 1987;p. 26
  61. Loehrer PJ, Ansary R, Gonin R, et al.  Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: A Hoosier Oncology Group study. J Clin Oncol. 1995;13:2594–2599
  62. Miyomoto H, Nakabayashi T, Isobe H, et al.  A phase III trial of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. Oncology. 1992;49:431–435
  63. Bunn PA, Kelly K. New treatment agents for advanced small cell and non–small cell lung cancer. Semin Oncol. 1995;22(suppl 6):53–63
  64. Glisson BS, Kurie JM, Perez-Soler R, et al.  Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J Clin Oncol. 1999;17:2309–2315
  65. Kelly K, Lovato L, Bunn PA, et al.  Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: A phase II trial of the Southwest Oncology Group. Clin Cancer Res. 2001;7:2325–2329
  66. Mavroudis D, Papadakis E, Veslemes M, et al.  A multicenter randomized phase II study comparing paclitaxel-cisplatin-etoposide (TEP) versus cisplatin-etoposide (EP) as front-line treatment in patients with small cell lung cancer (SCLC). Proc Am Soc Clin Oncol. 2000;19:484a; (abstr)
  67. Niell HB, Herndon JE, Miller AA, et al.  Randomized phase III intergroup trial (CALGB 9732) of etoposide and cisplatin with or without paclitaxel and G-CSF in patients with extensive stage small cell lung cancer. Proc Am Soc Clin Oncol. 2002;21:293a; (abstr)
  68. Hainsworth JD, Burris HA, Greco FA. Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: A review of the Sarah Cannon Cancer Center experience. Semin Oncol. 2001;28(suppl 4):43–47
  69. Thomas P, Castelnau O, Paillotin D, et al.  Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: A Group Francais de Pneumo-Cancerologie study. J Clin Oncol. 2001;19:1320–1325
  70. Jett JR, Day R, Levitt M, et al.  Topotecan and paclitaxel in extensive stage small cell lung cancer patients without prior therapy. Lung Cancer. 1997;18(suppl 1; abstr 28):13
  71. Schiller JH, Adak S, Cella D, et al.  Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593—A phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:2114–2122
  72. Kudoh S, Takada M, Masuda N, et al.  Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res. 1993;84:203–207
  73. Masumoto N, Nakano S, Esaki T, et al.  Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells. Int J Cancer. 1995;62:70–75
  74. Pei XH, Nakanishi Y, Takayama K, et al.  Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anticancer Drugs. 1997;8:231–237
  75. Kudoh S, Fujiwara Y, Takada Y, et al.  Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. J Clin Oncol. 1998;16:1068–1074
  76. Noda K, Nishiwaki Y, Kawahara M, et al.  Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85–91
  77. Turrissi AT, Kim K, Blum R, et al.  Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265–271
  78. Levitan N, Dowlati A, Shina D, et al.  Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma. J Clin Oncol. 2000;18:1102–1109
  79. Bremnes RM, Sundstrom S, Vilsik J, et al.  Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer. J Clin Oncol. 2001;19:3532–3538
  80. Ettinger DS, Seiferhels WF, Abrams RA, et al.  Cisplatin, etoposide, paclitaxel, and concurrent hyperfractionated thoracic radiotherapy for patients with limited disease small cell lung cancer: Preliminary results of RTOG 96009. Proc Am Soc Clin Oncol. 2000;19:490a; (abstr)
  81. Sandler A, Declerck L, Wagner H, et al.  A phase II study of cisplatin plus etoposide plus paclitaxel and concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): An Eastern Cooperative Oncology Group trial. Proc Am Soc Clin Oncol. 2000;19:491a; (abstr)

☆ Address reprint requests to Alan B. Sandler, MD, 777 Preston Research Bldg, Hematology/Oncology, Vanderbilt University, Nashville, TN 37232.

PII: S0093-7754(03)70039-6

doi: 10.1053/sonc.2003.50012

Seminars in Oncology
Volume 30, Issue 1 , Pages 9-25 , February 2003

Article Tools